SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: TheHungryHippo, Papa Bear, BluSkies, buythebuy, mtlebomac
Search This Board: 
Last Post: 5/27/2017 3:55:50 AM - Followers: 867 - Board type: Free - Posts Today: 13



Bioheart, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


The US. Stem Cell Inc. Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease.We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Charles A. Hart  53 Director
Sam Ahn  59 Director
Kristen Comella  37 Director, Chief Scientific Officer
Sheldon T. Anderson 63 Director


Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 

USRM - Daily Candlesticks


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
USRM News: Quarterly Report (10-q) 05/02/2017 04:06:21 PM
USRM News: Significant Updates on the Following Companies and New Coverage 04/20/2017 09:00:00 AM
USRM News: Grey Cloak Tech, Inc. (OTC Pink: GRCK), Acquires $6.4mm ShareRails, Inc. – $1.7 million in Sales, 300% Growth 04/12/2017 08:49:04 AM
USRM News: Grey Cloak Tech, Inc. (OTC Pink: GRCK), Acquires $6.4mm ShareRails, Inc. – $1.7 million in Sales, 300% Growth 04/12/2017 08:47:59 AM
USRM News: Statement of Changes in Beneficial Ownership (4) 03/31/2017 04:02:24 PM
#59623  Sticky Note TOP TEN REASONS I'M LONG ON $USRM RIGHT NOW. TheHungryHippo 05/13/17 01:34:26 AM
#52397  Sticky Note This is the guy who is investing up Vita Nova Stocks 04/15/17 09:22:22 AM
#42457  Sticky Note THIS IS A MUST READ slam4202 03/30/17 07:05:37 AM
#26891  Sticky Note $USRM ALL IN ONE DD Post for Investors: TheHungryHippo 03/09/17 05:25:50 AM
#64554   Staircase up. Chart bullish overall Company reformed RMAT approval in less atpavlovich 05/27/17 03:55:50 AM
#64553   USRM or last chance to get out for BoilerRoom 05/27/17 03:32:22 AM
#64552   usrm HUGE upstairs!! Boiler Room TINY downstairs. AbeFro 05/27/17 03:30:26 AM
#64551   I'm thinking that they'll opt for a more ThorBearPig 05/27/17 02:24:26 AM
#64550   Last chance to get in before RMAT approval. atpavlovich 05/27/17 01:46:48 AM
#64549   USRM catering truck was for the movers BoilerRoom 05/27/17 01:08:42 AM
#64548   I told you there would be balloons!!!! ;) Track 05/27/17 12:52:13 AM
#64547   USRM he's buying time so he can keep BoilerRoom 05/27/17 12:38:33 AM
#64546   We all invest in hopes here in the sorc92 05/27/17 12:14:19 AM
#64545   Well buddy I hope tuesday morning we see sorc92 05/27/17 12:10:26 AM
#64544   Don't invest on Hopes, bad idea!! wamugold 05/27/17 12:06:30 AM
#64543   News Is Coming for FDA Approval. BB Player 05/27/17 12:06:29 AM
#64542   There's no news he's making it up. wamugold 05/27/17 12:04:33 AM
#64541   USRM no news coming unless your involved with BoilerRoom 05/26/17 11:59:06 PM
#64540   sorc92, I BELIEVE USRM MGT. TEAM ALREADY HAS RECIEVED power11 05/26/17 11:56:44 PM
#64538   Good news ?? sorc92 05/26/17 11:50:44 PM
#64537   BOILER BABY, power11 05/26/17 11:41:28 PM
#64536   $USRM Going to $$$$$ Soon. BB Player 05/26/17 11:39:55 PM
#64535   Good day for USRM today. Held up very well. BB Player 05/26/17 11:38:32 PM
#64534   Getting closer to FDA Approval. BB Player 05/26/17 11:38:00 PM
#64533   I click on your posts to check out KRex0969 05/26/17 11:36:14 PM
#64532   USRM its always next week with this Turd BoilerRoom 05/26/17 11:30:54 PM
#64531   USRM Tuesday might be last day to get BoilerRoom 05/26/17 11:29:24 PM
#64530   Every One Have a Great Weekend. Blastoff Next Week. BB Player 05/26/17 11:10:49 PM
#64529   My guess is either after hours Wednesday or Tagprofenrir 05/26/17 10:37:10 PM
#64528   Lol your like a toned down version of hornet daytrader30000 05/26/17 10:22:17 PM
#64527   USRM some people want to steal your shares MyzStreet 05/26/17 10:21:27 PM
#64526   FDA APPROVAL VERY SOON! Time to Buy. BB Player 05/26/17 10:21:18 PM
#64525   Don;t wait to buy or you may be BB Player 05/26/17 10:19:37 PM
#64524   Grab all you can on Tuesday. FDA Approval anytime. BB Player 05/26/17 10:18:59 PM
#64523   Where and when ? Joeymc77 05/26/17 10:18:23 PM
#64522   USRM thoughts about this company have changed over BoilerRoom 05/26/17 10:17:02 PM
#64521   Quote" $USRM 99.9% we get approval" ;) great MyzStreet 05/26/17 09:59:25 PM
#64520   Everything I say is true to my best BoilerRoom 05/26/17 09:52:03 PM
#64519   That's the first thing you've said that is pennystocKING13 05/26/17 09:51:27 PM
#64518   USRM Government waste tax dollars on most everything BoilerRoom 05/26/17 09:48:36 PM
#64517   USRM thank you. Just keeping it real. BoilerRoom 05/26/17 09:47:48 PM
#64516   Youre an idiot. GoldenMind 05/26/17 09:47:29 PM
#64515   Have a great and safe weekend... BoilerRoom 05/26/17 09:47:22 PM
#64514   Your opinion clearly means a lot ! Cdizz123 05/26/17 09:46:55 PM
#64513   USEM you too.. Be safe BoilerRoom 05/26/17 09:46:38 PM
#64512   Have a great weekend GoldenMind 05/26/17 09:46:06 PM
#64511   No they won't. OTC_MILLIONAIR 05/26/17 09:44:52 PM
#64510   USRM will be denied IMHO BoilerRoom 05/26/17 09:35:59 PM
#64508   Don't catch that one because we like those MyzStreet 05/26/17 09:29:17 PM
#64507   I Agree Myz, Funny that Jbird17 Posted there bow-tie 05/26/17 09:13:29 PM
#64506   RMAT approval in the next 2 weeks. Don't atpavlovich 05/26/17 09:11:08 PM
#64505   Hi Saratg, to be honest with you I Newlife2017 05/26/17 09:08:19 PM
#64504   RMAT = BUYOUT The delay is the FDA deciding MyzStreet 05/26/17 09:06:06 PM
#64503   Longs, I'm really hoping for the huge news the third leg 05/26/17 08:49:56 PM